Papain-like Protease (SARS-CoV-2) Assay Kit: Deubiquitinase Activity

Catalog #
79996
$845 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Papain-like Protease Assay Kit: Deubiquitinase Activity is designed to measure Papain-like Protease deubiquitinating activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.

Papain-like Protease SARS-CoV-2 Assay Kit

Need us to run inhibitor screens or profile your compounds against Papain-like Protease (SARS-CoV-2): Deubiquitinase Activity? Check out our Protease Screening Services or Coronavirus Services

This product has been cited 6 times.

Synonyms
Severe acute respiratory Coronavirus, PLpro kit, PLP kit, Papain like protease assay
Product Info
Storage and Usage
Citations6
Assay Kit Format
Fluorogenic
Supplied As
The kit comes in a convenient 96-well format, with purified Papain-like Protease, ubiquitinated fluorogenic substrate, and PLPro assay buffer for 100 enzyme reactions. PLPro inhibitor GRL0617 is also included as a positive control.
Materials Required But Not Supplied

Fluorescent microplate reader capable of reading exc/em=360 nm/460 nm

Format
Catalog
Number

Component

Amount

Storage
100735 Recombinant Papain-like Protease, PLPro 2 x 2 µg -80°C





Avoid
freeze/
thaw
cycles!
  PLPro Ubiquitinated Substrate (25 µM) 50 µl -80°C
78039 PLPro Assay Buffer 25 ml -20°C
  10 mM GRL0617  20 µl -80°C
  0.5 M DTT 200 µl -20°C
79685 Black, low binding microtiter plate  1 Room
Temp
 
  Plate Sealing Film 1  
Background

Coronaviruses (CoVs) primarily cause multiple respiratory and intestinal infections in humans and animals. Papain-Like Protease (PLPro), also known as PLP, play an essential role in polypeptide processing during virus replication. PLPro, in addition to being crucial during replication via processing of the viral polyprotein, is proposed to be a key enzyme in the sustained pathogenesis of SARS-CoV. This includes deubiquitination (the removal of ubiquitin) from host-cell proteins. The last enzymatic activity result in the antagonism of the host antiviral innate immune response. As a result, PLpro is an important potential target for antiviral drugs that may inhibit viral replication and weaken dysregulation of signalling cascades in infected cells that may lead to cell death in surrounding, uninfected cells. PLPro inhibitors that can block viral replication are promising potential drug candidates that could be used to treat patients suffering with the COVID-19 coronavirus infection.

References

Ewelina Weglarz-Tomczak, et al., 2020. https://doi.org/10.1101/2020.05.17.100768.